ATHE NASDAQ
Alterity Therapeutics Limited
1W: -9.3%
1M: -26.3%
3M: -43.5%
YTD: +5.4%
1Y: -15.7%
3Y: +26.6%
5Y: -74.4%
$3.45
-0.04 (-1.15%)
Weekly Expected Move ±10.9%
$3
$3
$3
$4
$4
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Income Trends
Revenue
$0
-100.0% ▼
Gross Profit
-$113K
-102.1% ▼
Operating Income
-$28M
-90.7% ▼
Net Income
-$23M
-88.4% ▼
EPS (Diluted)
$-1.32
-15.8% ▼
EBITDA
-$28M
-89.2% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| Revenue | $5M | $4M | $4M | $5M | $0 |
| YoY Growth | +18.1% | -23.6% | +2.6% | +35.3% | -100.0% |
| Cost of Revenue | $365K | $285K | $214K | $128K | $113K |
| Gross Profit | $5M | $4M | $4M | $5M | -$113K |
| Gross Margin | 92.9% | 92.7% | 94.7% | 97.7% | — |
| R&D Expenses | $15M | $13M | $19M | $14M | $17M |
| SG&A Expenses | $6M | $5M | $5M | $5M | $10M |
| Operating Expenses | $20M | $18M | $23M | $20M | $28M |
| Operating Income | -$16M | -$15M | -$20M | -$15M | -$28M |
| Operating Margin | -302.6% | -373.7% | -487.7% | -268.0% | — |
| Interest Expense | $0 | $0 | $0 | $0 | $0 |
| Income Before Tax | -$13M | -$14M | -$19M | -$12M | -$26M |
| Tax Expense | $70K | $104K | $46K | $68K | -$3M |
| Net Income | -$13M | -$14M | -$19M | -$12M | -$23M |
| Net Margin | -250.7% | -352.5% | -475.8% | -223.4% | — |
| EPS (Diluted) | $-3.18 | $-3.42 | $-3.12 | $-1.14 | $-1.32 |
| EBITDA | -$17M | -$15M | -$20M | -$15M | -$28M |
| Shares Outstanding | 4M | 4M | 6M | 11M | 18M |